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Abstract
Brucella is the etiologic agent of brucellosis, one of the most common and widely distributed zoonotic diseases. Its highly
infectious nature, the insidious, systemic, chronic, debilitating aspects of the disease and the lack of an approved vaccine for
human use in the United States are features that make Brucella a viable threat to public health. One of the main
impediments to vaccine development is identification of suitable antigens. In order to identify antigens that could
potentially be used in a vaccine formulation, we describe a multi-step antigen selection approach. We initially used an
algorithm (Vaxign) to predict ORF encoding outer membrane proteins with antigenic determinants. Differential gene
expression during acute infection and published evidence for a role in virulence were used as criteria for down-selection of
the candidate antigens that resulted from in silico prediction. This approach resulted in the identification of nine Brucella
melitensis outer membrane proteins, 5 of which were recombinantly expressed and used for validation. Omp22 and Hia had
the highest in silico scores for adhesin probability and also conferred invasive capacity to E. coli overexpressing recombinant
proteins. With the exception of FlgK in the goat, all proteins reacted to pooled sera from exposed goats, mice, and humans.
BtuB, Hia and FlgK stimulated a mixed Th1–Th2 response in splenocytes from immunized mice while BtuB and Hia elicited
NO release from splenocytes of S19 immunized mice. The results support the applicability of the current approach to the
identification of antigens with immunogenic and invasive properties. Studies to assess immunogenicity and protective
efficacy of individual proteins in the mouse are currently underway.
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Introduction
Brucellosis is a zoonotic, chronic and debilitating systemic
disease of wide distribution but particularly important in European
countries along the Mediterranean, parts of Africa and Asia, the
Middle East and Central and South America [1,2]. Animals and
their food products are the primary source of human infection
where the mucosal routes are the most common modes of
transmission through inhalation and ingestion of animal-derived
contaminated materials, respectively [1,2,3,4,5,6,7]. Consistent
with the food animal-human symbiotic relationship, brucellosis is
one of the most common zoonotic diseases estimated at an annual
incidence of 500,000 cases [8]. Brucella, the etiologic agent, is
a Gram negative, facultative intracellular bacterium classified
based upon host preference where goat, swine, and cattle are
preferred by the most common agents implicated in human
brucellosis Brucella melitensis, Brucella suis, and Brucella abortus,
respectively [8,9,10,11,12]. The ability to efficiently infect through
mucosal surfaces and persist in the host, its highly infectious nature
and the insidious, systemic, chronic, debilitating aspects of the
disease are features that make Brucella a viable threat to public
health while earning it recognition by the CDC as a select agent
with potential use in a bioterrorist act [13]. At a time of emerging
and re-emerging disease and bioterrorist threats, the search for
protective measures in the form of novel, safe and effective
prophylactic and treatment options to mitigate effects of brucel-
losis is a challenge that needs to be urgently addressed.
The premise that vaccination is the single most important
approach to counteract infectious disease coupled with the threat
represented by Brucella has directed research efforts towards
development of a vaccine safe for human use. Based on the
comparative success of live-attenuated vaccines against intracellu-
lar pathogens, including Brucella, research efforts have focused on
the search for safer, live-attenuated vaccine candidates while the
search for immunogenic and protective subunit antigens is an area
that lacks, but merits, attention [13,14,15,16,17]. Consistent with
findings in Brucella research, one main reason for the difference in
conferred protection lies in the superiority of live-attenuated
organisms to stimulate effective adaptive immune responses,
particularly a T-cell response [14,17]. Deciphering the mechan-
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isms at play could potentially guide the design of a subunit vaccine.
Although attenuated, live intracellular organisms retain a residual
capacity to invade where they may produce an array of potential
immunogenic targets that are important for intracellular adapta-
tion, survival and replication [14,18,19]. The value of using
antigens that are over-expressed in the intracellular compartment
has been previously demonstrated [18,20]. In contrast, the target-
less traditional approach to antigen selection where subcellular
fractions of in vitro cultivated organisms are evaluated for pro-
tective efficacy undermines the quantitative, qualitative and
functional properties of the antigen preparation [21]. The
availability of genomic sequences and development of high
throughput genomics-dependent analytical methods such as
transcriptomics, proteomics, antigenomics and immunomics are
tools that could potentially accelerate development of targeted
approaches for identification of subunit antigens [22]. According-
ly, the availability of genomic sequences for several important
pathogens, including Brucella, has made the development of
genomics-based analytical tools to accelerate identification of
subunit immunogens possible [21].
Reverse vaccinology is a method that has yet to be applied to
Brucella but has proven useful in the identification of protective
antigens against other important pathogens [22]. Reverse
vaccinology is a concept that was first introduced in 2000 and is
based on the in silico genome analysis targeted at the identification
of antigens with desirable immunogenic, structural, or functional
characteristics [21,22]. In the current report, we use a reverse
vaccinology approach to select open reading frames (ORF)
encoding pre-determined immunogenic, functional, and structural
properties. Expressed encoded proteins and previously reported
functional genomics data were used to validate the predictive
ability of the analytical system.
Materials and Methods
Ethics Statement
All animal experiments were performed with the approval of the
Texas A&M University Institutional Animal Care and Use
Committee (AUP# 2010-0167). The use of unidentified human
serum samples was approved by the Institutional Review Board at
Texas A&M University (IRB protocol #2012-0412) based on 45
CFR 46.101(b)(4), from the US code of federal regulations.
Antigen Selection
Antigens were initially selected using in silico analysis of the
Brucella spp. genomes via the publicly available Vaxign program
(vaxign.com) [23]. The initial screening identified 27 candidate
ORFs. With the aid of published reports, the candidate ORFs
were further selected if they were co-regulated with known Brucella
virulence factors or had direct evidence for a role in pathogenesis.
The use of pathogenesis-associated bacterial factors as antigens in
vaccine preparations have been shown to confer protective
immunity against Brucella and other important intracellular
pathogens [24,25,26,27]. This resulted in 9 candidate ORFs. As
further evidence for a role in Brucella pathogenesis, global
transcriptomic data in in vivo and in vitro models of brucellosis
were used to verify that candidate ORFs were differentially
expressed during the acute phase of infection.
PCR Amplification Cloning and Transformant Selection
Primers were designed for the full-length amplification of selected
genes (Table 1). Open reading frames were amplified by polymerase
chain reaction (PCR) from B. melitensis 16M genomic DNA with the
PCR failsafe system (Epicentre Biotechnologies, WI, USA). PCR
amplicons were cloned into pET-SUMO and pTrc-His vectors
(Invitrogen, Carlsbad, CA.) using TA-TOPO cloning technology.
Constructswere introduced intoMach-1E. colicompetent cells.After
verification with restriction digestion and/or sequencing, plasmid
from positive transformants was obtained and used to transformBL-
21 (DE3) competent cells for protein expression.
Protein Expression
BL-21 E. coli cells transformed with the pET-SUMO-BME and
pTrcHis-BME constructs were grown to the log phase in Luria
Bertani broth (LB) supplemented with antibiotic and, when
appropriate, 1 mM glucose. For protein expression, log-phase
BL-21 bacteria expressing SUMO-fusion protein and his-tagged
protein were induced with 1 mM IPTG and incubated for 2.5
hours or 4.0 hours at 37uC, respectively. Following expression,
bacteria were pelleted and stored at 220uC until used. Protein
solutions and bacterial lysates were diluted with 26 SDS-PAGE
sample loading buffer and electrophoresed in 12.5% (w/v) SDS-
PAGE gels. Proteins were stained with Coomassie Blue to confirm
their size and level of purity.
Inclusion Body Isolation and Solubilization
OmpW, Omp22, Metal chelate Rc (BtuB), and Cell surface
protein (Hia) were primarily produced as inclusion bodies. With
slight modifications, inclusion bodies were purified as previously
described [28]. Briefly, bacterial pellets were suspended in native
purification buffer (NPB: 500 mM NaCl, 50 mM H2PO4, pH 8.0)
with lysozyme, incubated at room temperature and sonicated. The
resulting lysate was centrifuged at 5,0006g and the pellets were re-
suspended in cold PBS. This suspension was centrifuged at
10,0006g for 30 minutes and the recovered pellet was re-
suspended in PBS containing Triton X-100. This suspension was
centrifuged at 22,0006g for 15 minutes. The pellet recovered was
washed 3 times with PBS containing Triton X-100 and once with
PBS. The pellets were stored at 220uC until used. Prior to
purification, the pellets were solubilized in guanidinium lysis buffer
(6M guanidine HCl, 20 mM sodium phosphate, 500 mM NaCl,
pH 7.8) at 37uC.
Gel Filtration Chromatography and Refolding
Solubilized inclusion bodies or protein expressed in soluble form
were size-separated using Sephacryl S-300 resin (GE Healthcare,
WI, USA) via and eluted using 4M urea or native purification
buffer, respectively. Fractions were analyzed for purity via SDS-
PAGE, and the urea was subsequently removed using dialysis
against 16 or 26NPB, filter sterilized and then stored at 280uC
until use. Protein concentration was determined with the
Bradford-based Bio-Rad protein assay (Bio-Rad, CA, USA).
Invasion Studies
MLE-12 (ATCC, VA, USA), alveolar epithelial type II (AEII)
cells were plated at 2.56105 cells/well in 0.5 ml of DMEM media
and incubated overnight at 37uC with 5% (v/v) CO2. The
following day, cells were infected with BL-21 cells containing
pTrcHis-Brucella ORF constructs with or without IPTG stimu-
lation for the expression of B. melitensis recombinant outer
membrane proteins. After 30 minutes of incubation, gentamicin
was added at 100 mg/ml and incubated for 30 minutes to kill
extracellular bacteria. Cells were washed with PBS and sub-
sequently lysed with 1% Triton X-100 in PBS. Lysate was serially
diluted and bacteria enumerated by plating portions of serial
dilutions on LB agar. Invasion rate is calculated using the ratio of
bacteria recovered from the cells by the number of bacteria
Brucella Outer Membrane Protein Immunogenicity
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inoculated. Results were done in triplicate and the experiment was
repeated three times.
Western Blot
Pooled serum samples from 3 goats, .5 BALB/c mice, and 2
humans previously exposed to wildtype Brucella were pre-absorbed
with BL-21 E. coli lysate over-expressing the SUMO-CAT fusion
protein to eliminate backgroundand, subsequently, used as probes in
WesternBlot analysis.BL-21E. coli lysates overexpressingB.melitensis
16M recombinant outer membrane SUMO-fusion proteins were
electrophoresed in a SDS-PAGE gel. Separated proteins were
electroblotted in a wet system to nitrocellulose membrane and
blockedwith 5% (w/v) non-fat drymilk in PBS-T (0.1% (v/v) Tween
20 inPBS). Pooled serum samples fromBALB/cmice (1:1000), goats
(1:500) and humans (1:1000) were diluted in PBS-T+5% (w/v) NF
milk and themembranes were incubated in thismixture overnight at
4uCand thenwashed 3 timeswith PBS-T to remove excess antibody.
HRP-labeled secondary antibody specific to the primary antibody
was diluted 1:1000 and incubated with the membrane. Following
extensivewashing, the signalwas inducedby the additionof substrate
(Hy-Glo chemiluminescence system) according to the manufactures
instructions and captured using autoradiography film (Denville
Scientific Inc, NJ, USA). Images were stored as TIFF files and band
intensity quantified using the imageJ software (NIH,MA, USA). The
use of human serum samples was approved by the Texas A&M
University Institutional Review Board (IRB protocol#2012-0412).
Endotoxin Depletion
Frozen pellets were rapidly thawed using a 37uC water bath and
endotoxin depleted with endotoxin-depleting columns according
to manufacturer’s instructions (Norgen Biotek Corp, Canada).
Depletion of endotoxin was verified with the ToxinSensor
Chromogenic LAL endotoxin assay according to the instructions
of the manufacturer (GenScript, NJ, USA).
Animals and Immunization Protocol
Mice were obtained from Jackson laboratories (ME, USA) and
housed in approved facilities. Groups of 3 C57BL/6, female mice
were inoculated subcutaneously with PBS, ISCOMATRIX (CSL,
Parkville, Australia), 10 mg S19 lysate adjuvanted with 12 mg
ISCOMATRIX, or a protein cocktail consisting of 10 mg each
Hia, FlgK, and BtuB adjuvanted with 12 mg ISCOMATRIX.
Animals were similarly boosted 3 weeks post-priming and
euthanized three weeks following boosting for splenocyte analysis.
All experiments were performed with the approval of the Texas
A&M University Institutional Animal Care and Use Committee
(AUP# 2010-0167).
Primary Splenocyte Culture and Cytokine and Nitric
Oxide Release
Spleens from immunized and control mice were aseptically
removed and processed for single cell suspension. Splenocytes
were added to 96 well plates at 1.06105 cells/well in 200 ml RPMI
media. The cells were stimulated with 7 mg of corresponding
protein and incubated at 37uC for 24 hours. Supernatants were
collected and stored at 220uC until use. Cytokines in the
supernatants were analyzed with the Bio-Rad bioplex system
using a Luminex 200 analyzer according to the manufacturer’s
instructions (Bio-Rad, CA, USA). Analysis of IL-17A, was
performed via ELISA according to the manufacturer’s instructions
(eBioscience, CA, USA). Nitric oxide release was measured using
the Griess reagent system per the instructions of the manufacturer
(Promega, WI, USA). Surplus splenocytes were frozen and stored
in 280uC until use. When the cytokine level was below the lowest
value recorded for the standard, the sample was arbitrarily
assigned the lowest value of the standard range.




Antigens were selected using in silico analysis of the Brucella spp.
genomes via the publicly available Vaxign program (vaxign.com)
[23]. Options for the in silico screening of the Vaxign program
include subcellular location, presence of T cell epitopes, adhesin
probability, presence or absence of orthologs in selected bacterial
strains, and similarity to host proteins. Using the Brucella melitensis
16M genome as the reference, selection criteria for the present
study included open reading frames that coded for proteins present
in the outer membrane due to the importance of the outer
membrane in Brucella pathogenesis, contained MHCI and MHCII
epitopes in mouse and humans, have adhesin potential, have
orthologs present in Brucella suis and Brucella abortus, and lastly,
proteins with no similarity to human, or mouse proteins. With the
described settings, initial screening resulted in 27 candidate ORFs.
The number of candidate antigens was reduced through the
selection of only those ORFs that had been ascribed, through
published reports, a direct or indirect role in virulence of Brucella
spp. Bacterial factors that support infection of Brucella spp. and
other intracellular agents have been demonstrated to have
protective value against infection when used as immunogens as
indicated above [24]. First, published transcriptomics and
proteomics reports on virB and BvrR-BvrS two-component system,
two important virulence factors of Brucella spp., were used
[29,30,31,32]. Open reading frames encoding proteins co-regu-
lated with these virulence factors were included for further
Table 1. Brucella melitensis 16M Genes and Proteins.
Gene Forward Primer Reverse Primer Protein MW (Da)
BMEI0454 59-ATGGCAGCCACCGCGCTC-39 59-TCAGAAACGGTAGGTAATACCGGTG-39 OmpW 23, 541
BMEI0536 59-ATGAACACTCGTGCTAGCAATTTTCT-39 59-TTACTTGATTTCAAAAACGACATTGACCGATACG-39 Bp26 26, 552
BMEI0657 59-ATGGCGCAGGATGGCGGGGATAAG-39 59-TCAGAAATTACGGGTCAGCCC-39 BtuB 64, 807
BMEI0717 59-ATGGGAGGGACCGACTACACCTATAAC-39 59-CTAGAATTTGTAGTTCAGGCCG-39 Omp22 19, 448
BMEI1872 59-ATGCCGATGGCCCGTCATC-39 59-TTAATTGAAGGTATAGCTGAAACCTGCC-39 Hia 37, 461
BMEII0160 59-ATGTCACTTAGTTCTGCTCTTCTGACGG-39 59-TCACACCGCGTTAAGAAGATCATC-39 FlgK 50, 596
doi:10.1371/journal.pone.0059751.t001
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analyses. Direct evidence was defined as a gene or protein for
which a direct role in the invasion or adaptation of Brucella has
been defined or orthologs in other pathogens for which a role in
virulence has been established. Brucella spp. possesses a Hia
autotransporter with homology to an adhesin and colonization
factor in Haemophilus influenzae, an important human pathogen of
the respiratory tract [33]. An ABC-autotranporter, BtuB, has been
observed to support survival of Brucella melitensis 16M in the mouse
macrophage [15]. Lastly, Brucella spp. contains an operon that
codes for a flagellum. The FlgK gene, which was predicted by the
algorithm, is included in such operon. It was recently reported that
this operon is required to establish a chronic infection in the mouse
model of brucellosis (19, 51). Following this methodology, the
resulting list consisted of 9 open reading frames.
To further support a virulence role for the antigens in Brucella, the
dynamicsof geneexpressionduring theacutephaseof infection in the
HeLa cell [19] and the previously described calf ligated ileal loop
model system [34,35,36]. Down regulation of gene expression
following host cell internalization, relative to inoculum, is consistent
with a role in invasionwhile inductionof gene expression is consistent
with a role in adaptation of the bacterium to the intracellular niche.
From among the 27 proteins initially identified using Vaxign, nine
were identified thatmatched the additional criteria applied andwere
prepared for evaluation via expression in E. coli.
Protein Expression and Purification
Protein expression was induced in BL-21 E. coli cells harboring
either pET-SUMO-BME or pTrcHis-BME constructs. Log phase
bacterial cultures were treated with 1 mM IPTG to stimulate
protein expression that was evaluated at several time points post-
induction. OmpW, BtuB, Omp22, Hia, and Flgk were successfully
expressed at sufficient levels as SUMO-fusion proteins by 2.5
hours post-stimulation (Fig. 1). Of 9 candidates selected for
expression, 5 proteins were expressed at levels permitting analysis
of their vaccine potential (Figs. 1 and 2). Proteins were optimally
expressed under the control of the pTrc promoter by 4 to 4.5
hours post-IPTG stimulation (Fig. 3).
Recombinant B. melitensis Omp22 and Hia Confer
Invasive Properties on Non-invasive BL-21 E. Coli Strain
Based on the premise that selection of candidate outer
membrane proteins included an elevated probability of identifying
adhesins, a role for candidate proteins in invasion of mouse
alveolar type II epithelial cells was explored. Given that the
aerogenous route is a highly effective and common portal of
Brucella infection, efforts focused on a determination of mouse
alveolar epithelial cell support of infection and replication of
Brucella. To assess this possibility, B. abortus S19 was used to infect
the type II alveolar epithelial cell line, MLE-12 in gentamicin
protection assays. MLE-12 cells infected at an MOI of 500 as
described in the Materials and Methods section. The capacity to
infect alveolar epithelial cells was confirmed by consistent,
intracellular bacterial recovery following infection. Bacteria
numbers were slightly decreased by 8 hrs post-infection but
progressively increased by 24 and 48 hrs, exceeding the level of
bacteria uptake (Fig. 4A) and supporting the potential contribution
of these cells to infection and persistence. The results shown are
inclusive of three independent experiments performed in triplicate.
To determine whether the capacity to infect ATII cells was
derived from any of the candidate immunogens non-invasive BL-
21 E. coli strain over-expressing individual Brucella outer mem-
brane proteins were evaluated for infection of ATII cells (Fig. 3).
Following a 30-minute infection period, only BL-21 E. coli cells
over-expressing Omp22 and Hia were able to enter epithelial cells.
Compared to BL-21 cells expressing the non-relevant LacZ
protein, Omp22 and Hia conferred invasive capacity on the
non-invasive BL-21 cells (Fig. 4B).
Mice, Goats and Humans Exposed to Wild Type Brucella
spp. Mount Antibody Responses to Brucella melitensis
16M Outer Membrane Proteins
To evaluate the humoral immune response against selected
candidate antigens, pooled sera derived from wildtype Brucella spp.-
exposed goats, BALB/c mice and humans was pre-absorbed using
E. coli lysate and used to evaluate expression of B. melitensis 16M
recombinant outer membrane proteins in E. coli lysates by Western
Blots. Antibody reponses directed against the majority of the
proteins were observed (Fig. 5, panels A and B). With the
exception of FlgK probed with goat sera, all proteins were reactive
with sera from exposed humans, goats, and mice. BP26, a known
immunodominant protein, was used as positive control. While the
sera from goat and mouse produced a greater signal against major
Group 3 membrane proteins Omp22 and OmpW, human sera
exhibited a greater response to non-Group 3 membrane proteins
Hia and FlgK (Fig. 5, panels A and B).
Figure 1. Whole cell lysate from BL-21 E. coli transformed with pET-SUMO-BME constructs. Bacteria were grown to log phase in LB broth
supplemented with antibiotic and then stimulated with IPTG for 2.5 hours. Bacterial lysates were diluted with SDS loading buffer, incubated at 95uC
for 5 minutes and electrophoresed in a 12.5% SDS-PAGE gel.
doi:10.1371/journal.pone.0059751.g001
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B. melitensis 16M Recombinant Outer Membrane
Proteins Elicit Nitric Oxide Release from Splenocytes
Nitric oxide (NO) plays a role in multiple physiologic functions
including immunogenic responses and brucellacidal activity
[37,38,39,40]. To investigate whether candidate Brucella outer
membrane proteins elicit release of nitric oxide, single recombi-
nant outer membrane proteins of Brucella melitensis 16M were used
to stimulate primary splenocytes derived from S19 lysate-
immunized mice and NO release quantified. The B. abortus S19
lysate, BtuB and Hia, but not FlgK, elicited release of significant
nitric oxide from S19 lysate splenocytes (Fig. 6).
B. melitensis 16M Outer Membrane Protein-mediated T
Cell Cytokine Production in Splenocytes
The three highest scoring proteins with regards to predicted
humanandmouseMHCepitopeswere selected todetermineantigen
specific T-cell responses (Table 2). Cytokine responses of splenocytes
derived frommice immunizedwithacocktailofproteinswereantigen
specificas thoseresponsesweredetermined in vitroafter stimulationof
immune splenocytes with individual antigens. Furthermore, pre-
liminary results in our laboratory indicate that S19 lysate inoculation
induces protective immunity against Brucella (unpublished data).
Inoculationwithacocktailconsistingof thehighest scoringantigens in
this study was an effort to emulate the heterogeneity of the S19 lysate
formulation. Groups of three mice were primed and boosted three
weeks apart with a cocktail of BtuB, Hia, and FlgK recombinant
proteins or S19 lysate formulated with ISCOMATRIX adjuvant.
Three weeks after boosting, spleens were collected and processed for
primary splenocyte culture. Splenocytes were stimulated with single
recombinant protein and culture supernatant collected to determine
antigen-specific cytokine responses. Cytokine analysis resulting from
antigen-specific stimulation was reflective of a hybrid Th1–Th2
response. Although a mixed T-cell response, the magnitude of
secretedTh1derivedcytokines, IFN-candIL-2,wasgreater thanthat
represented by a Th2 response, IL-4, IL-5 and IL-10 for all three
proteins evaluated (Fig. 7). These findings support the availability of
an environment conducive to amore potent Th1 thanTh2 response
that results from either the microenvironment created by the
adjuvant-antigen complex and/or inherent immune determinants
of the antigen. Primary splenocytes were also stimulated to release
TNF-a in the presence of recombinant protein or S19 lysate (Fig. 7).
Figure 2. Purified Brucella melitensis 16M outer membrane proteins expressed as SUMO-fusion proteins in BL-21 E. coli cells. OmpW,
BtuB, Omp22, and cell surface protein expressed in inclusion bodies were purified by centrifugation, solubilized with guanidine HCl, and separated in
gel filtration column. Bacterial lysates containing BP26 and FlgK in the soluble fraction were directly purified in an S-300 gel filtration column. Purified
protein fractions were diluted with SDS loading buffer, incubated at 95uC for 5 minutes and electrophoresed in a 12.5% SDS-PAGE gel.
doi:10.1371/journal.pone.0059751.g002
Figure 3. Bacterial lysates from BL-21 E. coli transformed with pTrc-BME constructs and used as inoculums in mouse alveolar type II
epithelial cells invasion assays. Bacteria were grown to log phase in LB broth supplemented with antibiotic followed by the addition or exclusion
of IPTG and 4 hours of continued incubation. Bacterial lysates were diluted with SDS loading buffer, incubated at 95uC for 5 minutes and
electrophoresed in a 12.5% SDS-PAGE gel. Lanes 1, 3, 5, 7, 9, lysate from BL-21 cells stimulated with IPTG and overexpressing OmpW, BtuB, Omp22,
cell surface protein, and FlgK (arrows), respectively. Lanes 2, 4, 6, 8, 10, lysates from non-stimulated BL-21 cells containing protein expression
constructs for OmpW, BtuB, Omp22, cell surface protein, and FlgK.
doi:10.1371/journal.pone.0059751.g003
Brucella Outer Membrane Protein Immunogenicity
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To further characterize the immune response, IL-17 release into the
supernatant was also quantified. Although to a lesser degree than for
Th1 and Th2 responses, the antigen elicited significant IL-17
responses insplenocytes recovered fromall recombinantproteinsand
S19 vaccinated mice (Fig. 7).
Discussion
Brucellosis represents a public health threat of global significance
for which a vaccine capable of providing protection against human
infection is lacking [41]. Consistent with the lack of vaccine, the
traditional approach to the identification of subunit protective
antigens is tedious and often anunrewarding endeavor [21].Reverse
vaccinology is a genomics-based in silico predictive tool with early
success and future promise in the identification of protective antigens
against important animal andhumanpathogens [22,42].Despite the
surfacing of promising results, reverse vaccinology has yet to be
applied toBrucella. In thepresent study,weintegrated in silico sequence
Figure 4. Invasion of mouse alveolar type II epithelial cells
(MLE12) with Brucella abortus S19 (A) or BL21 E. coli over-
expressing Brucella melitensis 16M outer membrane proteins
(B). A. Mouse alveolar MLE12 epithelial cells were plated at 2.56105
with DMEM media. The following day, cells were infected with log
phase B. abortus S19 or BL21 E. coli +/2 IPTG stimulation at an MOI of
500:1. Extracellular bacteria were eliminated in a 30-minutes incubation
period in the presence of gentamicin that followed a 30-minute
invasion period. Mouse cells were lysed and plated in LB with ampcillin
or TSA media. B. abortus invasion is reported as number of bacteria
recovered at different time-points. BL-21 invasion as reported as the
number of bacteria recovered after 30 the minute invasion divided by
the number of bacteria inoculated. Data represent the mean +/2 SEM
from three independent experiments in triplicate. Statistical significance
was determined with one-tailed Student’s t-test (*P,0.05).G.
doi:10.1371/journal.pone.0059751.g004
Figure 5. Western blot of pooled serum from exposed goats,
mice, and humans to recombinant Brucella melitensis 16M
outer membrane proteins. BL21 E. coli lysates overexpressing
Brucella outer membrane proteins were electrophoresed and trans-
ferred to a nitrocellulose membrane. Recombinant proteins were
probed with serum absorbed against E. coli lysates overexpressing
SUMO-CAT. Secondary antibodies labeled with HRP were used and
cheluminescence used for signal development. Signals were developed
in autoradiography film (A) and captured as Tiff images and analyzed
with imageJ software (B). To determine fold change, signal intensity
against Brucella proteins bands was divided by the intensity produced
against control protein SUMO-CAT.
doi:10.1371/journal.pone.0059751.g005
Figure 6. Nitric oxide release from splenocytes derived from
mice inoculated with S19 lysate and stimulated with Brucella
outer membrane proteins. A group of three C57BL/6 mice were
inoculated subcutaneously with S19 lysate twice three weeks apart and
humanely euthanized 3 weeks after the last inoculation. Spleens were
harvested and processed into a single cell suspension. Splenocytes
were plated and stimulated with individual Brucella outer membrane
proteins BtuB, Hia, and FlgK. Supernatants were collected 24 hrs post-
stimulation and analyzed for nitric oxide release using the promega
griess reagent system. Data represent mean +/2 standard error of the
mean from 3 mice. Statistical significance between PBS control and
treatment groups was determined with one-tailed Student’s t-test
(*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0059751.g006
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analysis, functional genomics, proteomics, and virulence-relevant
data into a multi-step antigen selection approach to identify
immunogenic Brucella melitensis 16M outer membrane protein
candidates. By following this approach, we were able to identify
novel candidate outer membrane proteins that conferred invasive
properties to E. coli which suggest a role in Brucella invasion, elicited
humoral and T cell responses, and stimulated nitric oxide release by
splenocytes frommice immunized with S19 lysate.
The critical role that virulence factors play in the pathogenesis
of infectious agents makes them desirable candidates for vaccine
development due to their implied conserved nature [17].
Accordingly, a salient aspect of Brucella is its highly effective ability
to penetrate host mucosal membranes and infect a variety of non-
phagocytic and professional phagocytic cells
[43,44,45,46,47,48,49]. Among susceptible cell types, the host
alveolar epithelial cell is of particular interest to our laboratory due
to the ability of Brucella to establish an infection via the aerogenous
route at a relatively low dose [11]. It was previously demonstrated
that the A549 human alveolar epithelial cell line is susceptible to
Brucella infection and replication [49]. Accordingly, we demon-
strated that Brucella also infects and replicates in mouse alveolar
Type II epithelial cells, thereby, affording us a tool to evaluate
invasive properties of candidate Brucella outer membrane proteins.
In support of the predictive ability of the vaxign program, the two
proteins with the highest adhesin scores, Hia and Omp22,
conferred a dose dependent (IPTG induced vs. non-induced)
invasive phenotype to the non-invasive BL-21 E. coli strain in
mouse Type II cells. These results are supported by prior reports
attributing an invasive function to Brucella Omp22 and a role in
colonization to Haemophilus influenzae protein, Hia [33,50]. These
data suggest that Brucella outer membrane proteins Omp22 and
Hia are successfully produced and transported to the surface of E.
coli, as previously observed, but does not confirm proper folding of
proteins or translocation of proteins lacking invasive functionality
[51]. Targeted deletion of genes encoding B. melitensis candidate
proteins is currently underway in an effort to confirm and
understand their overall contribution to invasion.
Although selection of antigens associated with virulence of
a pathogen is a valuable and common practice due to their implied
indispensable and, hence, conserved nature, their ability to be
recognized by the immune system and elicit desired responses is an
aspect that must take precedence in the selection process [17]. An
effective adaptive immune response is critical for protection
against brucellosis. The importance of this branch of the immune
system has been established by protection studies targeting the role
of T-cells and humoral immunity [52,53,54,55,56,57]. These
observations are consistent with the growing evidence indicating
that antibodies have a protective role against intracellular bacterial
infections [58]. Despite reports of Brucella outer membrane
proteins eliciting immune responses, characterization of their















Bovinea 15 m: 22.01 15 m: +1.68 15 m: 26.95 15 m: 213.63 15 m: +2.51 N/A
120 m: 21.72 120 m: +3.44 120 m: 28.13 120 m: 211.86 120 m: +2.69
HeLa [19] 4 h: 29.97 4 h: +2.66 4 h: 25.63 4 h: 22.36 4 h: +2.94 N/A
12 h: 221.03 12 h: +2.58 12 h: 26.15 12 h: 21.74 12 h: +3.7
16M Mutagenesis [15] N/A Attenuated N/A N/A N/A N/A
BvrR/S- B. abortus [31,32] – – – N/A N/A N/A
Immunoreactivityb
Human 2.2 2.4 2.7 3 3.1 2.2
Mouse 5.2 1.3 3.6 3.2 1.5 3.5
Goat 3.5 1.8 6 2.1 0.6 3.3
Vaxign Program [23]
Adhesin Probability 0.586 0.504 0.609 0.656 0.39 N/A
Human MHCI score 0.296545 0.361865 0.263562 0.288301 0.339568 N/A
Human MHCII Score 0.32461 0.382724 0.30115 0.344729 0.337355 N/A
Mouse MHCI Score 0.341885 0.416492 0.314076 0.345491 0.392729 N/A
Mouse MHCII Score 0.310426 0.37862 0.291076 0.359367 0.353167 N/A
Outer Membrane Score 1 1 0.992 0.992 0.949 N/A
Additional notes Homology to
Colonization
Role in Chronic Immunogenic in
Factor in
H. Influenzae [33]
Infection in Mice [67] Goat/Human [68]
aRosseti, CA, et. al., manuscript in preparation.
bImageJ analysis.
(2) gene or protein is down regulated.
16M- Brucella melitensis 16M.
N/A- not available.
doi:10.1371/journal.pone.0059751.t002
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specific immunogenicity and potential contribution to protection
have not been fully explored [10]. Western blot analysis indicated
that serum from three Brucella-exposed hosts had varying IgG
responses to the candidate proteins. These results indicate their
ability to elicit humoral responses across host species and may be
of value when targeting immunity in multiple hosts, a highly
desirable feature of an immunization protocol against this
important zoonotic disease.
Although evidence for a role of antibody responses in the
protection against brucellosis remains a subject of controversy, an
important role for T-cell responses is well accepted [59,60].
Adaptive T-cell immunity includes activation and responses of
CD4+ or CD8+ T-cells. The protection against brucellosis that is
conferred by CD4+ T-cells is primarily through secretion of
relevant cytokines that stimulate other immunocytes to eliminate
Brucella [48,56,61]. In order to secrete cytokines, T-cells must
recognize antigen in the context of MHC molecules. Th1, Th2
and Th17 are CD4+ cells that rely on the presentation via the
MHCII complex [62]. Specifically, evidence exists that supports
the role of Th1 and Th17 products in protection against
brucellosis [48,61,63]. The Th1 products, IFNc and TNF-a and
the Th-1 supportive cytokine IL-12 have been correlated with
protection against intracellular pathogens including Brucella
[60,61,64]. On the other hand, activation of Th2 cells and
secretion of associated cytokines has been linked to chronic,
relapsing brucellosis [65]. Recently, a role in subunit vaccine-
induced protection for IL-17 was demonstrated in mice [63]. To
support in silico prediction and selection of antigens bearing T cell
epitopes, antigen-specific recall responses from splenocytes derived
from mice immunized with a cocktail of Hia, FlgK, and BtuB
proteins elicited secretion of Th1, Th2 and Th17 cytokines.
Although a mixed T-cell response, the premise that the magnitude
of Th1 cytokine secretion exceeded that of Th2-derived cytokines
justifies their inclusion in future protection studies. The adjuvant
used in this study was selected based on its ability to support T-cell
activation and its safety aspect. ISCOMATRIX has been shown to
support Th1, Th2 and antibody responses. Additionally, the ability
of ISCOMATRIX to promote cross presentation and activation of
CD8+ T cells and the demonstrated role of CD8+ T cells in
clearance of brucellosis also weighed on our decision to include in
our studies [66]. In contrast, the widely used aluminum based
adjuvants are good at promoting Th2 and antibody responses but
they do not promote CD8+ T cell responses to the degree that
ISCOMATRIX does [66]. One of the many roles of helper T-cell
derived cytokines is to stimulate immunocytes such as macro-
phages to produce and secrete nitric oxide, a chemical linked to
clearance of Brucella [37,40]. Candidate antigen-specific stimula-
tion resulted in significantly greater NO secretion in splenocytes
derived from S19 lysate-immunized mice. Again, providing
justification for their further evaluation as immunogens.
Taken together, our study indicates that in silico analysis
provides the ability to predict Brucella antigens that exhibit
immunogenic and invasive properties. Mouse studies including
single antigen inoculations to assess immunity and protection
against B. melitensis 16M are currently underway.
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